Journal of Bone and Mineral Metabolism

, Volume 30, Issue 2, pp 202–207 | Cite as

Physical training increases osteoprotegerin in postmenopausal women

  • Ingrid BergströmEmail author
  • Paolo Parini
  • Sven A. Gustafsson
  • Göran Andersson
  • Jonas Brinck
Original Article


The purpose of this study was to explore whether mechanical loading by exercise over a 1–year period in postmenopausal women had an effect on the receptor activator for nuclear factor kappa B ligand/osteoprotegerin (RANKL/OPG) system or the levels of the Wnt-signaling antagonist sclerostin. A total of 112 postmenopausal were randomized to either sedentary life (controls) or physical activity (training group). Ninety-two women fulfilled the study protocol. The training program consisted of three fast 30-min walks and one or two 1-h aerobic training sessions per week. The effect on the bone mineral density of the hip assessed with dual X-ray absorptiometry was positive as reported earlier. Blood samples were taken from participants at baseline and after 1 year and serum levels of OPG, RANKL and sclerostin were quantified together with the bone metabolism markers C-terminal telopeptide of collagen type I (CTX) and bone-specific alkaline phosphatase (BALP). The results were analyzed using an analysis of covariance model using baseline values as the covariate. The training group displayed a clear mean increase of OPG +7.55 pg/ml compared to controls (p = 0.007). The mean changes for RANKL +0.19 pg/ml (square-root transformed data) and sclerostin +0.62 pmol/l were non-significant (p = 0.13 and p = 0.34). The changes in bone turnover markers CTX and BALP showed a tendency to decrease in the training group versus controls but the changes were small and non-significant. Although our study is limited in number of participating women, we have been able to show an OPG-associated, and RANKL- and sclerostin-independent, training-induced inhibition of postmenopausal bone loss.


Physical training Postmenopausal women Osteoprotegerin Receptor activator for nuclear factor κB ligand Sclerostin 



We wish to thank Ingela Arvidsson and Lilian Larsson for excellent technical assistance. This study was supported by grants from the Stockholm County Council (ALF) and Swedish Research Council (VR-M K2009-52X-10363-17-3).


  1. 1.
    Prince RL, Draper C (2000) Bone and calcium. In: Lobo RA, Kelsey J, Marcus R (eds) Menopause. Academic Press, USA, pp 287–294CrossRefGoogle Scholar
  2. 2.
    Lian JB, Stein GS (2001) Osteoblast biology. In: Marcus R, Feldman D, Kelsey J (eds) Osteoporosis. Academic Press, San Diego, pp 33–35Google Scholar
  3. 3.
    Kim CH, You L, Yellowley CE, Jacobs CR (2006) Oscillatory fluid flow-induced shear stress decreases osteoclastogenesis through RANKL and OPG signaling. Bone 39:1043–1047PubMedCrossRefGoogle Scholar
  4. 4.
    You L, Temiyasathit S, Lee P, Kim CH, Tummala P, Yao W, Kingery W, Malone AM, Kwon RY, Jacobs CR (2008) Osteocytes as mechanosensors in the inhibition of bone resorption due to mechanical loading. Bone 42:172–179PubMedCrossRefGoogle Scholar
  5. 5.
    Vega D, Maalouf NM, Sakhaee K (2007) CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab 92:4514–4521PubMedCrossRefGoogle Scholar
  6. 6.
    Garnero P (2009) Bone markers in osteoporosis. Curr Osteoporos Rep 7:84–90PubMedCrossRefGoogle Scholar
  7. 7.
    Avbersek-Luznik I, Gmeiner Stopar T, Marc J (2007) Activity or mass concentration of bone-specific alkaline phosphatase as a marker of bone formation. Clin Chem Lab Med 45:1014–1018PubMedCrossRefGoogle Scholar
  8. 8.
    Pacifici R (1996) Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 11:1043–1051PubMedCrossRefGoogle Scholar
  9. 9.
    Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, Holmes GB, Dunstan CR, DePaoli AM (2004) A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19:1059–1066PubMedCrossRefGoogle Scholar
  10. 10.
    Samelson EJ, Broe KE, Demissie S, Beck TJ, Karasik D, Kathiresan S, Kiel DP (2008) Increased plasma osteoprotegerin concentrations are associated with indices of bone strength of the hip. J Clin Endocrinol Metab 93:1789–1795PubMedCrossRefGoogle Scholar
  11. 11.
    Saunders MM, Taylor AF, Du C, Zhou Z, Pellegrini VD Jr, Donahue HJ (2006) Mechanical stimulation effects on functional end effectors in osteoblastic MG-63 cells. J Biomech 39:1419–1427PubMedCrossRefGoogle Scholar
  12. 12.
    Mehrotra M, Saegusa M, Wadhwa S, Voznesensky O, Peterson D, Pilbeam C (2006) Fluid flow induces Rankl expression in primary murine calvarial osteoblasts. J Cell Biochem 98:1271–1283PubMedCrossRefGoogle Scholar
  13. 13.
    Tang L, Lin Z, Li YM (2006) Effects of different magnitudes of mechanical strain on Osteoblasts in vitro. Biochem Biophys Res Commun 344:122–128PubMedCrossRefGoogle Scholar
  14. 14.
    Kusumi A, Sakaki H, Kusumi T, Oda M, Narita K, Nakagawa H, Kubota K, Satoh H, Kimura H (2005) Regulation of synthesis of osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand in normal human osteoblasts via the p38 mitogen-activated protein kinase pathway by the application of cyclic tensile strain. J Bone Miner Metab 23:373–381PubMedCrossRefGoogle Scholar
  15. 15.
    West SL, Scheid JL, De Souza MJ (2009) The effect of exercise and estrogen on osteoprotegerin in premenopausal women. Bone 44:137–144PubMedCrossRefGoogle Scholar
  16. 16.
    Ziegler S, Niessner A, Richter B, Wirth S, Billensteiner E, Woloszczuk W, Slany J, Geyer G (2005) Endurance running acutely raises plasma osteoprotegerin and lowers plasma receptor activator of nuclear factor kappa B ligand. Metabolism 54:935–938PubMedCrossRefGoogle Scholar
  17. 17.
    Noble BS (2008) The osteocyte lineage. Arch Biochem Biophys 473:106–111PubMedCrossRefGoogle Scholar
  18. 18.
    Piters E, Boudin E, Van Hul W (2008) Wnt signaling: a win for bone. Arch Biochem Biophys 473:112–116PubMedCrossRefGoogle Scholar
  19. 19.
    Moustafa A, Sugiyama T, Saxon LK, Zaman G, Sunters A, Armstrong VJ, Javaheri B, Lanyon LE, Price JS (2009) The mouse fibula as a suitable bone for the study of functional adaptation to mechanical loading. Bone 44:930–935PubMedCrossRefGoogle Scholar
  20. 20.
    Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MR, Alam I, Mantila SM, Gluhak-Heinrich J, Bellido TM, Harris SE, Turner CH (2008) Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 283:5866–5875PubMedCrossRefGoogle Scholar
  21. 21.
    Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, Mangiafico RA, Pulvirenti I, Hawa G, Tringali G, Fiore CE. Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab 95; 2248−2253Google Scholar
  22. 22.
    Bergstrom I, Landgren B, Brinck J, Freyschuss B (2008) Physical training preserves bone mineral density in postmenopausal women with forearm fractures and low bone mineral density. Osteoporos Int 19:177–183PubMedCrossRefGoogle Scholar
  23. 23.
    Bergstrom I, Lombardo C, Brinck J (2009) Physical training decreases waist circumference in postmenopausal borderline overweight women. Acta Obstet Gynecol Scand 88:308–313PubMedCrossRefGoogle Scholar
  24. 24.
    Price JS, Sugiyama T, Galea GL, Meakin LB, Sunters A, Lanyon LE. Role of endocrine and paracrine factors in the adaptation of bone to mechanical loading. Curr Osteoporos Rep 9; 76−82Google Scholar
  25. 25.
    Bergstrom I, Freyschuss B, Landgren BM (2005) Physical training and hormone replacement therapy reduce the decrease in bone mineral density in perimenopausal women: a pilot study. Osteoporos Int 16:823–828PubMedCrossRefGoogle Scholar
  26. 26.
    Reid IR (2008) Relationships between fat and bone. Osteoporos Int 19:595–606PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society for Bone and Mineral Research and Springer 2011

Authors and Affiliations

  • Ingrid Bergström
    • 1
    Email author
  • Paolo Parini
    • 2
  • Sven A. Gustafsson
    • 3
  • Göran Andersson
    • 4
  • Jonas Brinck
    • 1
  1. 1.Division of Endocrinology, Metabolism and DiabetesKarolinska University Hospital, Karolinska InstitutetStockholmSweden
  2. 2.Division of Clinical ChemistryKarolinska University Hospital, Karolinska InstitutetStockholmSweden
  3. 3.Division of Clinical Chemistry, Department of Molecular MedicineKarolinska University Hospital, Karolinska InstitutetStockholmSweden
  4. 4.Division of PathologyKarolinska University Hospital, Karolinska InstitutetStockholmSweden

Personalised recommendations